Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 8:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 54,906 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Patient Clear all
Completed Phase 2 Interventional Results available

A Phase II Study of Bermekimab (MABp1) in Patients With Moderate to Severe Atopic Dermatitis

NCT03496974
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Bermekimab Monoclonal Antibody 200 mg, Bermekimab Monoclonal Antibody 400 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Mar 12, 2021 · Synced Oct 31, 2026, 8:14 PM EDT
Completed Phase 2 Interventional Results available

Irinotecan and Cisplatin in Treating Patients Who Are Undergoing Surgery For Locally Advanced Cancer of the Stomach or Gastroesophageal Junction

NCT00062374
View directory record Official record
Conditions
Gastric Adenocarcinoma, Stage II Gastric Cancer, Stage III Gastric Cancer, Stage IV Gastric Cancer
Interventions
Cisplatin, Computed Tomography, Fludeoxyglucose F-18, Fluorothymidine F-18, Irinotecan Hydrochloride, Positron Emission Tomography, Therapeutic Conventional Surgery
Drug · Procedure · Radiation + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 6, 2017 · Synced Oct 31, 2026, 8:14 PM EDT
Completed No phase listed Observational

A Study to Evaluate Conceptual Saturation of Evaluating Respiratory Symptoms (E-RS) in Subjects With Asthma

NCT03344406
View directory record Official record
Conditions
Asthma
Interventions
Telephonic interviews, E-RS: COPD, Supplemental asthma items, Daily diary, Sociodemographic questionnaire, Clinical questionnaire
Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 31, 2026, 8:14 PM EDT
Terminated Not applicable Interventional Results available

Effects of Neuro-Stim System on Pain, Sleep, and Opioid Use

NCT02673684
View directory record Official record
Conditions
Pain (Visceral, Somatic, or Neuropathic)
Interventions
Experimental NSS, Sham NSS
Device
Lead sponsor
Defense and Veterans Center for Integrative Pain Management
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 27, 2020 · Synced Oct 31, 2026, 8:14 PM EDT
Completed Phase 4 Interventional Results available

A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus

NCT02688933
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
HOE901-U300 (Insulin Glargine 300 U/ml), Lantus (Insulin Glargine 100 U/ml), Mandated back ground therapy
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 70 Years
Enrollment
638 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
99
States / cities
Little Rock, Arkansas • Concord, California • Escondido, California + 80 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Oct 31, 2026, 8:14 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study of CIM331 for Atopic Dermatitis Patients

NCT01986933
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
nemolizumab (CIM331), Placebo
Drug · Other
Lead sponsor
Chugai Pharmaceutical
Industry
Eligibility
18 Years to 65 Years
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
18
States / cities
Anniston, Alabama • San Diego, California • Miami, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2022 · Synced Oct 31, 2026, 8:14 PM EDT
Recruiting Phase 3 Interventional

Dapagliflozin in Patients With Atrial Fibrillation (DAPA-AF)

NCT05174052
View directory record Official record
Conditions
Diabetes Mellitus, Atrial Fibrillation
Interventions
Dapagliflozin 10Mg Tab, Placebo
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 85 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 31, 2026, 8:14 PM EDT
Active, not recruiting Not applicable Interventional

Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI & Multivessel Disease

NCT05701358
View directory record Official record
Conditions
Acute Myocardial Infarction, Coronary Artery Disease
Interventions
Physiology-guided NCL PCI, Angiography-guided NCL PCI
Procedure
Lead sponsor
Population Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
5,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
14
States / cities
Los Angeles, California • San Francisco, California • Wichita, Kansas + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 31, 2026, 8:14 PM EDT
Completed Not applicable Interventional Results available

Low Frequency Deep Brain Stimulation of the Subthalamic Nucleus in Parkinson's Disease

NCT03204526
View directory record Official record
Conditions
Parkinson Disease, Cognitive Impairment
Interventions
deep brain stimulation
Device
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 23, 2021 · Synced Oct 31, 2026, 8:14 PM EDT
Completed Phase 2 Interventional

A Multi-Institutional Phase II Study of Cyclophosphamide, Paclitaxel, Cisplatin With G-CSF for Patients With Newly Diagnosed Advanced Stage Ovarian Cancer

NCT00001426
View directory record Official record
Conditions
Ovarian Neoplasm
Interventions
Cyclophosphamide, Paclitaxel, Cisplatin, G-CSF
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Female only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Oct 31, 2026, 8:14 PM EDT
Terminated No phase listed Observational Results available

Arrythmia Burden in Cardiac Contractility Modulation (CCM)

NCT05704426
View directory record Official record
Conditions
Atrial Fibrillation, Arrythmia
Interventions
Impulse Dynamics Optimizer Device
Device
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Oct 31, 2026, 8:14 PM EDT
Completed Phase 3 Interventional Results available

Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2)

NCT03656926
View directory record Official record
Conditions
Bronchiolitis Obliterans, Chronic Rejection of Lung Transplant, Lung Transplant Rejection, Lung Transplant; Complications, Lung Transplant Failure and Rejection, Chronic Lung Allograft Dysfunction
Interventions
Liposomal Cyclosporine A, Standard of Care
Drug
Lead sponsor
Zambon SpA
Industry
Eligibility
18 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
21
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 31, 2026, 8:14 PM EDT
Recruiting Early Phase 1 Interventional

Effects of a Probiotic Intervention on the Gut and Vaginal Microbiome in Patients With Advanced or Recurrent Ovarian Cancer Undergoing Treatment With Platinum Chemotherapy

NCT07144826
View directory record Official record
Conditions
Advanced Ovarian Carcinoma, Recurrent Ovarian Carcinoma, Stage II Ovarian Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8
Interventions
Biospecimen Collection, Placebo Administration, Probiotic, Questionnaire Administration
Procedure · Drug · Dietary Supplement + 1 more
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 31, 2026, 8:14 PM EDT
Completed Early Phase 1 Interventional

Pilot Study of Imatinib Cetuximab Combo for H & N Cancer

NCT05816785
View directory record Official record
Conditions
Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck
Interventions
Cetuximab, Imatinib
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 31, 2026, 8:14 PM EDT
Terminated Not applicable Interventional Results available

Early Detection and Intervention for Mild and Moderate Lymphedema in Patients Treated for Breast Cancer

NCT00959985
View directory record Official record
Conditions
Lymphedema, Breast Cancer
Interventions
Compression Sleeve, Short-Stretch Compression Bandage
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 31, 2026, 8:14 PM EDT
Completed Not applicable Interventional Results available

A Pilot Trial of Itraconazole Pharmacokinetics in Patients With Metastatic Breast Cancer

NCT00798135
View directory record Official record
Conditions
Breast Neoplasms, Neoplasm Metastasis
Interventions
itraconazole
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Oct 31, 2026, 8:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Falls - Tailoring Interventions for Patient Safety

NCT00675935
View directory record Official record
Conditions
Patient Falls
Interventions
Fall Prevention Tool Kit prototype using a randomized design
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 110 Years
Enrollment
10,264 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 17, 2024 · Synced Oct 31, 2026, 8:14 PM EDT
Terminated Phase 3 Interventional Results available

Study of Fentanyl-Propofol-EMLA of L.M.X4 Technique for Bone Marrow Aspiration

NCT00187135
View directory record Official record
Conditions
Bone Marrow Disease, Pain
Interventions
Fentanyl, EMLA, L.M.X4, Propofol
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
2 Years to 17 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 31, 2026, 8:14 PM EDT
Terminated Phase 2 Interventional

A Phase II Trial of TPI 287 in Patients With Metastatic Prostate Cancer

NCT00479635
View directory record Official record
Conditions
Prostate Cancer
Interventions
TPI 287
Drug
Lead sponsor
Cortice Biosciences, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
6
States / cities
Los Angeles, California • Palm Springs, California • Lexington, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2014 · Synced Oct 31, 2026, 8:14 PM EDT
Completed Phase 4 Interventional Results available

Glargine Dosing in Hospitalized Patients With Type 2 Diabetes and Renal Insufficiency

NCT00911625
View directory record Official record
Conditions
Type 2 Diabetes, Renal Insufficiency
Interventions
0.5 units/kg daily insulin, 0.25 units/kg daily insulin
Drug
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
3
States / cities
Chicago, Illinois • Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 6, 2017 · Synced Oct 31, 2026, 8:14 PM EDT
Completed Phase 1 Interventional

XAD - Xelox (Capecitabine + Oxaliplatin) + Bevacizumab + Dasatinib

NCT00920868
View directory record Official record
Conditions
Solid Tumor, Metastatic Colorectal Cancer
Interventions
dasatinib, bevacizumab, Oxaliplatin, Capecitabine
Drug
Lead sponsor
Herbert Hurwitz, MD
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
2
States / cities
Denver, Colorado • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 3, 2016 · Synced Oct 31, 2026, 8:14 PM EDT
Completed Phase 1Phase 2 Interventional

Topotecan Plus Sargramostim in Treating Patients With Advanced Cancer

NCT00002950
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
sargramostim, topotecan hydrochloride
Biological · Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 120 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2002
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 17, 2020 · Synced Oct 31, 2026, 8:14 PM EDT
Completed Phase 2 Interventional Results available

Pemetrexed Disodium and Gemcitabine in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

NCT00407550
View directory record Official record
Conditions
Lung Cancer
Interventions
gemcitabine HCL, pemetrexed disodium
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 2, 2019 · Synced Oct 31, 2026, 8:14 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Relationship Between Diet, Lifestyle, and the Severity of Coronary Artery Disease

NCT02382250
View directory record Official record
Conditions
Dietary Habits, Coronary Artery Disease, Lifestyle
Interventions
Survey
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
440 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced Oct 31, 2026, 8:14 PM EDT